Sorrento Therapeutics Inc

-0.17 (-2.10%)
Products, Regulatory, Other Pre-Announcement

Scilex Holding Company A Subsidiary Of Sorrento Therapeutics Announces Continuous Sales Growth In Ztlido And Expects To Complete Enrollment On Its Sp-102 Phase 3 Pivotal Trial Program In 2020

Published: 10/07/2020 10:11 GMT
Sorrento Therapeutics Inc (SRNE) - Scilex Holding Company, a Subsidiary of Sorrento Therapeutics, Announces Continuous Sales Growth in Ztlido® and Expects to Complete Enrollment on Its Sp-102 (semdexa™) Phase 3 Pivotal Trial Program in 2020.
Scilex Holding Company- Expects Q3 2020 Ztlido Net Sales to Grow 26% to Approximately $7.2mm Compared to $5.7mm in Q2-2020.
Scilex Holding Company - Phase 3 Pivotal Trial Investigating Sp-102 Non-opioid Therapy Top-line Data Expected to Be Announced by Q2-2021.
Scliex Holding Company - Pivotal Phase 3 Clinical Trial Expected to Complete Enrollment in Q4 of 2020.